Lam Research (LRCX) CEO sells shares and exercises options in 10b5-1 plan

Rhea-AI Filing Summary

Lam Research Corp. reported insider trading activity by its President and CEO on 12/17/2025. The filing shows sales and an option exercise in Lam Research common stock carried out under a Rule 10b5-1 trading plan adopted on August 19, 2025.

The CEO sold 50,000 shares of common stock at $163.86 per share, then exercised an employee stock option for 113,300 shares at an exercise price of $17.675 per share. Those 113,300 shares were then sold on the same day at $163.86 per share. After these transactions, the CEO directly beneficially owned 932,409 shares of Lam Research common stock, which includes shares subject to unvested restricted stock units.

The filing also lists indirect holdings of 48,025.816 shares through a 401(k) plan and 5,670.097 shares through the spouse's 401(k) plan, reflecting additional indirect economic exposure to Lam Research stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARCHER TIMOTHY

(Last) (First) (Middle)

4650 CUSHING PARKWAY

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LAM RESEARCH CORP [ LRCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2025		S		50,000(1)	D	$163.86	932,409(2)	D
Common Stock	12/17/2025		M		113,300(1)	A	$17.675	1,045,709(2)	D
Common Stock	12/17/2025		S		113,300(1)	D	$163.86	932,409(2)	D
Common Stock								48,025.816	I	By 401(k)
Common Stock								5,670.097	I	By Spouse 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$17.675	12/17/2025		M			113,300(1)	(3)	03/01/2026	Common Stock	113,300	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025

2. The amount reported includes shares subject to unvested restricted stock units.

3. The stock options will become exercisable in three equal installments on 03/01/2020, 03/01/2021, and 03/01/2022.

Remarks:

	Marta Woods by Power of Attorney	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lam Research (LRCX) report for its CEO?

The President and CEO of Lam Research Corp. reported stock sales and an option exercise on 12/17/2025. He sold 50,000 shares of common stock and also exercised an employee stock option covering 113,300 shares, which were then sold the same day.

At what prices did the Lam Research (LRCX) CEO trade shares on 12/17/2025?

The CEO sold Lam Research common stock at $163.86 per share. He exercised an employee stock option with an exercise price of $17.675 per share for 113,300 underlying shares, which were then sold at $163.86 per share.

How many Lam Research (LRCX) shares does the CEO own after the reported transactions?

Following the reported transactions, the CEO directly beneficially owned 932,409 shares of Lam Research common stock. This amount includes shares subject to unvested restricted stock units.

Were the Lam Research (LRCX) CEO trades made under a Rule 10b5-1 plan?

Yes. The filing states that the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025.

What employee stock option did the Lam Research (LRCX) CEO exercise?

The CEO exercised an employee stock option (right to buy) for 113,300 shares of common stock at an exercise price of $17.675 per share. After the exercise, 0 derivative securities remained beneficially owned from that option.

What indirect Lam Research (LRCX) holdings does the CEO report?

The filing shows indirect ownership of 48,025.816 shares of Lam Research common stock through a 401(k) plan and 5,670.097 shares through the CEO's spouse's 401(k) plan.